Follitropin Delta: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), HIRA (South Korea) and PBAC (Australia), among others, recommended or restricted follitropin delta, while AWMSG (Wales) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded restricted for “Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (I…”, while AWMSG (Wales) recorded not recommended for “Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive techn…”.
Where follitropin delta met resistance it was usually narrowed rather than refused: 3 of 7 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
Assessment has run over 7 years, from 2017 at PBAC (Australia) to 8 Jul 2024 at SMC (Scotland).
No assessment is on file from PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for follitropin delta by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 7 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess follitropin delta, in 2017; SMC (Scotland) did not open a file until 8 Jul 2024 — a wide spread of 7 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 3 of 7 dated records fall in 2017 alone.
Restriction is doing real work here: 3 of 7 decisive outcomes narrowed follitropin delta to a subgroup rather than accepting or refusing it outright, at HIRA (South Korea), SMC (Scotland) and TLV (Sweden).
HAS (France) is the only agency to have returned to follitropin delta, recording 2 separate entries.
6 of the 18 agencies in this archive hold a record for follitropin delta.
The full ledger for follitropin delta reads 3 restricted, 3 recommended and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 8 Jul 2024 | Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (I… | accepted (restricted) | source |
| HAS (France) | 10 Apr 2024 | Re-examination following new data | SMR substantial · ASMR V | source |
| TLV (Sweden) | 26 Apr 2021 | Rekovelle ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| HIRA (South Korea) | 8 May 2020 | 보조생식술을 받는 여성에서 조절된 난소 자극 | reimbursable only at the evaluated price | source |
| AWMSG (Wales) | 12 Jul 2017 | Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive techn… | not endorsed (non-submission) | source |
2 further decisions for follitropin delta, across 2 agencies, are not shown here. They link to 1 further source document.
Related molecules
- follitropin alfa — divergent outcome (restricted vs recommended) on a shared indication
- progesterone — divergent outcome (restricted vs recommended) on a shared indication
- choriogonadotropin alfa — same ATC class G03G — Sex hormones and modulators
- empagliflozin — also decided by SMC in 2024Q3
- ivosidenib — also decided by SMC in 2024Q3
- ivacaftor / lumacaftor — also decided by SMC in 2024Q3
Coverage: 7 decisions for follitropin delta from 6 agencies, 2017 to 2024. Data to 7 Sep 2026. ATC class G03G — Sex hormones and modulators. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.